Lates News

According to a brief from Every AI, Donghai Securities released a research report on October 30th, giving a "buy" rating to Hubei Biocause Pharmaceutical Co., Ltd. (000513.SZ). The reasons for the rating mainly include: 1) performance basically meets expectations; 2) the formulation sector is steadily growing, while the raw material sector is slightly declining; 3) the research and development pipeline is entering a harvest period, and overseas expansion is constantly advancing. (Daily Economic News)